Breaking

Oct 23, 2020 1 min, 43 secs

Stay connected to what's important in medical research and clinical practice?

Free full text is available with an account for a limited time.

A complete list of the FIDELIO-DKD investigators is provided in the Supplementary Appendix, available at NEJM.org

In this double-blind trial, we randomly assigned 5734 patients with CKD and type 2 diabetes in a 1:1 ratio to receive finerenone or placebo

In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org

This article was published on October 23, 2020, at NEJM.org

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org

From the Department of Medicine, University of Chicago Medicine, Chicago (G.L.B.); the Richard L

Roudebush Veterans Affairs Medical Center and Indiana University, Indianapolis (R.A.); the Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin (S.D.A.), and Research and Development, Statistics and Data Insights (P.S.), and Cardiology and Nephrology Clinical Development (A.J.), Bayer, Berlin, and Research and Development, Preclinical Research Cardiovascular (P.K.) and Clinical Development Operations (C.N.), Bayer, Wuppertal — both in Germany; the Department of Medicine, University of Michigan School of Medicine, Ann Arbor (B.P.); the Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research i+12, Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares, Hospital Universitario 12 de Octubre, and the Faculty of Sport Sciences, European University of Madrid — all in Madrid (L.M.R.); Steno Diabetes Center Copenhagen, Gentofte, and the Department of Clinical Medicine, University of Copenhagen, Copenhagen — both in Denmark (P.R.); and the National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens (G.F.)

Bakris at the Department of Medicine, University of Chicago, 5841 S

A complete list of the FIDELIO-DKD investigators is provided in the Supplementary Appendix, available at NEJM.org

This content requires an NEJM.org account

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED